Welcome to our dedicated page for Biocardia news (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on Biocardia stock.
BioCardia, Inc. (NASDAQ: BCDA) generates news centered on its development of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease. As a clinical-stage company headquartered in Sunnyvale, California, its updates often relate to progress in late-stage trials, regulatory interactions, and advances in its enabling delivery and imaging technologies.
Investors and clinicians following BCDA news can expect regular coverage of the CardiAMP autologous cell therapy platform in ischemic heart failure with reduced ejection fraction (HFrEF) and chronic myocardial ischemia with refractory angina, as well as the CardiALLO allogeneic mesenchymal stem cell platform in ischemic heart failure. Recent announcements have highlighted Phase 3 CardiAMP HF II trial enrollment at leading centers, subgroup efficacy signals from prior trials, and discussions with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) on the potential approvability of CardiAMP Cell Therapy for HFrEF.
News items also address BioCardia’s Helix transendocardial biotherapeutic delivery system, Morph vascular navigation platform, and Heart3D fusion imaging platform, including updates on planned regulatory submissions and performance in preclinical and clinical settings. Corporate developments such as leadership appointments, board changes, financing activities, and Nasdaq listing compliance updates are disclosed through press releases and corresponding SEC filings.
This BCDA news page brings together these announcements so readers can follow clinical milestones, regulatory consultations, device platform progress, and governance developments in one place. For those tracking investigational therapies in heart failure, refractory angina, and related conditions, the BioCardia news feed provides an ongoing view into how the company’s programs and platforms are evolving over time.
BioCardia (NASDAQ: BCDA) announced the designation of a new reimbursement code, C9782, by the U.S. Centers for Medicare and Medicaid Services (CMS) for its CardiAMP® Cell Therapy procedure. This code, effective April 1, 2022, allows hospitals to receive reimbursement for studies involving autologous bone marrow cell treatment for heart failure. This designation supports ongoing pivotal trials in two cardiovascular indications, enhancing CMS's commitment to treating ischemic heart failure and providing financial clarity for clinical institutions involved in these trials.
BioCardia (Nasdaq: BCDA) announced the receipt of a No Objection Letter from Health Canada, allowing the expansion of its CardiAMP Heart Failure Trial into Canada. The Phase III trial, which is currently enrolling patients in the U.S., aims to assess the effectiveness of CardiAMP Cell Therapy for patients with ischemic cardiomyopathy. Four Canadian clinical sites are preparing to start patient enrollment soon. CEO Peter Altman noted that the rigorous approval process has strengthened the trial, which utilizes innovative patient selection and delivery methods to enhance treatment outcomes.
BioCardia, Inc. (Nasdaq: BCDA) announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the Phase III pivotal CardiAMP™ Cell Therapy Heart Failure Trial. The DSMB confirmed no significant safety concerns and recommended continuation of the trial, which has enrolled 108 patients. CEO Peter Altman stated that the trial is positioned to meet its primary endpoint and aims to enroll 260 patients across 40 centers. The trial utilizes proprietary techniques to enhance patient outcomes.
BioCardia, Inc. (Nasdaq: BCDA) announced that the FDA has granted Breakthrough Device Designation for its CardiAMP® Cell Therapy System aimed at treating heart failure. This designation marks it as the first cardiac cell therapy to receive such status. The therapy utilizes a patient's own bone marrow cells delivered minimally invasively, intending to enhance treatment efficacy and patient safety. Currently, the CardiAMP Heart Failure Trial is enrolling patients to assess the therapy's effectiveness, with promising past results indicating significant improvements in exercise tolerance and quality of life.
BioCardia (Nasdaq: BCDA) announced its participation in two virtual investor meetings: the H.C. Wainwright BioConnect Virtual Conference from January 10-13 and the Biotech Showcase from January 10-12. CEO Dr. Peter Altman and CFO David McClung will engage in one-on-one meetings with investors during these events. Interested institutional or retail investors can request meetings through the conference platforms. BioCardia develops biotherapeutics for cardiovascular and respiratory diseases, driven by its CardiAMP and NK1R+ platforms.
BioCardia has announced a long-term lease for a new facility in Sunnyvale, California, aimed at enhancing the manufacturing of its cell and device products. This facility will support the development of BioCardia's CardiAMP Cell Therapy Systems, NK1R+ MSC, and Biotherapeutic Delivery Devices for clinical trials and early commercial activities. The company’s CEO emphasized the strategic importance of maintaining manufacturing proximity to accelerate product development and innovation, indicating expectations for multiple therapeutic programs to progress in clinical settings.
BioCardia, Inc. (BCDA) reported Q3 2021 results showing a revenue increase to $821,000, up from $34,000 year-over-year. The net loss narrowed to $2.7 million compared to $3.8 million in Q3 2020. The CardiAMP® Cell Therapy trial faces enrollment challenges due to COVID-19 but has enrolled 106 patients across 24 sites. Upcoming milestones include data reviews and IND submissions for various therapies. The company ended the quarter with $15.9 million in cash.
BioCardia, Inc. (NASDAQ:BCDA), a developer of cell-derived therapeutics for cardiovascular and pulmonary diseases, will release its third quarter 2021 financial results on November 10, 2021, at 4:30 PM ET. The company focuses on two biotherapeutic platforms: CardiAMP for cardiovascular indications and NK1R+ for potential treatments in cardiovascular and pulmonary diseases. These platforms support four product candidates aimed at benefiting millions of patients.
BioCardia, Inc. (BCDA) announced the treatment of the first patient in its Phase III CardiAMP Cell Therapy trial targeting chronic myocardial ischemia. Conducted at the University of Wisconsin, the trial aims to enroll up to 343 patients at 40 centers, focusing on improving exercise tolerance at six months. The treatment utilizes the patient's bone marrow cells delivered via a minimally invasive procedure. Additionally, the FDA approved a protocol amendment to shorten the follow-up period to six months. This trial may also enhance enrollment in the concurrent Heart Failure Study.
BioCardia recently announced the issuance of U.S. Patent No: 11,141,568 for a Multi Directional Steerable Catheter, enhancing its Helix™ Biotherapeutic Delivery System. This technology aims to improve physician control during cardiac procedures by reducing torque issues. The patented catheter is integrated into the FDA-cleared Morph® DNA™ guide and AVANCE™ introducer, expected to bolster their clinical biotherapeutics in heart disease. BioCardia estimates a significant market opportunity with approximately 1.6 million potential U.S. patients for its therapies, alongside a growing $490 million transseptal access market.